Literature DB >> 15530698

Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene.

Hilde Hansen1, Malachy Ifeanyi Okeke, Oivind Nilssen, Terje Traavik.   

Abstract

Some poxviruses are very attractive as transgenic vaccine vectors for humans, domestic animals and wildlife. Poxviridae family members circulate in different ecosystems and parts of the world, providing a pool of possible recombination partners for released or escaped genetically modified poxviruses. We performed in vitro double infections with a vaccinia virus strain Ankara (MVA) vectored influenza vaccine and a cowpox virus isolate from Norway, isolated hybrids, and further analyzed three hybrid viruses with different plaque phenotypes. One of the hybrids was genetically unstable, and during adaptation to new host cells its MVA derived influenza gene was deleted at a high frequency. This is significant in a risk assessment context, since the transgene would be the only logical tag for monitoring unwanted spread and non-target effects of a vaccine virus. Putative recombination events involving genetically modified and naturally occurring viruses should be included in health and environmental risk assessments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530698     DOI: 10.1016/j.vaccine.2004.06.032

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Virological and Immunological Outcomes of Coinfections.

Authors:  Naveen Kumar; Shalini Sharma; Sanjay Barua; Bhupendra N Tripathi; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2018-07-05       Impact factor: 26.132

2.  Comparative sequence analysis of A-type inclusion (ATI) and P4c proteins of orthopoxviruses that produce typical and atypical ATI phenotypes.

Authors:  Malachy Ifeanyi Okeke; Olayiwola A Adekoya; Ugo Moens; Morten Tryland; Terje Traavik; Øivind Nilssen
Journal:  Virus Genes       Date:  2009-10       Impact factor: 2.332

3.  Genome sequence of SG33 strain and recombination between wild-type and vaccine myxoma viruses.

Authors:  Christelle Camus-Bouclainville; Magalie Gretillat; Robert Py; Jacqueline Gelfi; Jean Luc Guérin; Stéphane Bertagnoli
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

4.  Identification of nucleotide-level changes impacting gene content and genome evolution in orthopoxviruses.

Authors:  Eneida L Hatcher; Robert Curtis Hendrickson; Elliot J Lefkowitz
Journal:  J Virol       Date:  2014-09-17       Impact factor: 6.549

Review 5.  Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.

Authors:  Martine Goossens; Katia Pauwels; Nicolas Willemarck; Didier Breyer
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

Review 6.  CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development.

Authors:  Arinze Okoli; Malachy I Okeke; Morten Tryland; Ugo Moens
Journal:  Viruses       Date:  2018-01-22       Impact factor: 5.048

Review 7.  Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.

Authors:  Aline Baldo; Amaya Leunda; Nicolas Willemarck; Katia Pauwels
Journal:  Vaccines (Basel)       Date:  2021-05-03

8.  In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.

Authors:  Malachy Ifeanyi Okeke; Øivind Nilssen; Ugo Moens; Morten Tryland; Terje Traavik
Journal:  Virol J       Date:  2009-05-12       Impact factor: 4.099

Review 9.  Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations.

Authors:  Amaya Leunda; Aline Baldo; Martine Goossens; Kris Huygen; Philippe Herman; Marta Romano
Journal:  Vaccines (Basel)       Date:  2014-06-16

Review 10.  Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?

Authors:  Malachy I Okeke; Arinze S Okoli; Diana Diaz; Collins Offor; Taiwo G Oludotun; Morten Tryland; Thomas Bøhn; Ugo Moens
Journal:  Viruses       Date:  2017-10-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.